etanidazole
Sign in to saveAlso known as N-(2-Hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide, N-(2-Hydroxyethyl)-2-nitroimidazole-1-acetamide, N-(2-Hydroxyethyl)-1-(2-nitro-1-imidazolyl)acetamide
Etanidazole is a nitroimidazole drug that was investigated in clinical trials for its radiosensitizing properties in cancer treatment. Administration of etanidazole results in a decrease of glutathione concentration and inhibits glutathione S-transferase. The result is that tissues become more sensitive to the ionizing radiation.
Research
329 papers- Pharmacology and clinical investigation of SR-2508 (etanidazole).Cancer treatment and research · 1991
- Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.Biomaterials · 2007
- Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-bearing chick embryo.Journal of radiation research · 2011
- Modification of the aerobic cytotoxicity of etanidazole.International journal of radiation oncology, biology, physics · 1994
- PEG modulated release of etanidazole from implantable PLGA/PDLA discs.Biomaterials · 2002
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 214.07
- Has use
- medication
Show 5 more facts
- chemical formula
- C₇H₁₀N₄O₄
- canonical SMILES
- C1=CN(C(=N1)[N+](=O)[O-])CC(=O)NCCO
- World Health Organisation international non-proprietary name
- etanidazole
- subject has role
- radiosensitizer
- Commons category
- Etanidazole
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Etanidazole is a nitroimidazole drug that was investigated in clinical trials for its radiosensitizing properties in cancer treatment. Administration of etanidazole results in a decrease of glutathione concentration and inhibits glutathione S-transferase. The result is that tissues become more sensitive to the ionizing radiation.
==See also== 18F-EF5, a related nitroimidazole Misonidazole
Excerpted from Wikipedia’s “etanidazole” article, available under the CC BY-SA 4.0 licence.